LONDON – The rise of digital health and the application of artificial intelligence and big data, to preserves such as drug discovery, real-world patient monitoring and the analysis of medical images, is forcing investors in traditional life sciences startups out of their comfort zone and propelling them to form syndicates with tech venture capitalists.